TENAX THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
TENAX THERAPEUTICS, INC. (TENX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $2.72 per share for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2016-11-09
- TENAX THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.00.
- TENAX THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-07-31 was $3.42, a 29.05% decline year-over-year.
- TENAX THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2014-07-31 was $4.82, a 2.55% increase year-over-year.
- TENAX THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2013-07-31 was $4.70, a 165.54% increase year-over-year.
- TENAX THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2014 was $5.64, a 82.70% decline from fiscal 2013.
- TENAX THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2013 was $32.60, a 15.98% decline from fiscal 2012.
- TENAX THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2012 was $38.80.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2016-09-30 | $2.72 10-Q · filed 2016-11-09 | |||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-10 | |||
| 2015-10-31 | $3.48 10-Q · filed 2015-12-10 | |||
| 2015-07-31 | $3.42 10-Q · filed 2015-09-09 | |||
| 2015-01-31 | $4.82 10-Q · filed 2015-03-17 | |||
| 2014-10-31 | $4.82 10-Q · filed 2014-12-15 | |||
| 2014-07-31 | $4.82 10-Q · filed 2014-09-15 | |||
| 2014-04-30 | $5.64 10-K · filed 2014-07-29 | |||
| 2014-01-31 | $4.69 10-Q · filed 2014-03-17 | |||
| 2013-10-31 | $4.69 10-Q · filed 2013-12-17 | |||
| 2013-07-31 | $4.70 10-Q · filed 2013-09-17 | |||
| 2013-04-30 | $32.60 10-K · filed 2014-07-29 | |||
| 2013-01-31 | $1.67 10-Q · filed 2013-03-18 | |||
| 2012-10-31 | $1.70 10-Q · filed 2012-12-14 | |||
| 2012-07-31 | $1.77 10-Q · filed 2012-09-19 | |||
| 2012-04-30 | $38.80 10-K · filed 2013-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |